Impact of Topical Nepafenac on Macular Thickness after Phacoemulsification with Intraocular Lens Implantation in Patients without Diabetic Retinopathy
Objective: To study the effect of post-operative Non-Steroidal Anti-inflammatory (NSAID) eye drops on macular thickness in patients without diabetic retinopathy measured by Optical Coherence Tomography (OCT).
Study Design: Quasi-experimental study.
Place & Duration of the Study: Ophthalmology Department/ Lahore General Hospital, Lahore from 15-01-2019 to 31-12-2021.
Materials and Methods: Diabetic patients without retinopathy who required cataract surgery for visual rehabilitation were included in the study. They were then divided into two groups. Group A included patients who received routine steroid+antibiotic post-operative drops while Group B comprised of patients who received nepafenac (0.1%) eye drops eight hourly in addition to routine post-operative eye drops. All patients underwent standard phacoemulsification and intraocular lens implantation followed by the use of NSAID eye drops for a month. OCT measurements were done pre-operatively, 7 and 28 days post-operatively.
Results: Comparison of central macular thickness between groups was significant at (Pre & 7-day post-op) and insignificant at (7th day & 28th day post-op) and (Pre & 28th day post-op) i.e. 0.043, 0.834, and 0.084 respectively. However, a difference in mean central macular thickness was significant at all follow-up periods i.e.0.003, 0.006, and 0.000.
Conclusion: Post-operative NSAID in diabetic patients without retinopathy leads to a significant decrease in macular thickness as compared to controls after cataract surgery.
Pattern of Cataract Surgery Indications. Ophthalmology. 2015;122(1):31-38.
2-Gogate P, Jaggernath JB, Deshpande S, Naidoo K. Meta-analysis to Compare the Safety
and Efficacy of Manual Small Incision Cataract Surgery and Phacoemulsification. Middle
East Afr J Ophthalmmol. 2015;22(3):362-369.
3-Bajpayee N, Tidake PK, Palsodkar PM. Comparitive study of visual acuity and astigmatism
determination between small incision cataract surgery and phacoemulsification by corneal
topography. Int J Curr Res Rev. 2020;22(12):65-68.
4-Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS
5- Deka A. Comparative study of topical steroids vs nonsteroidal anti-inflammatory drugs to
control postcataract surgery inflammation. J Cat & Ref Surg. 2020;46(10):1397-1401.
6-Kee TL, Graff G, Spellman JM, Yanni JM. Nepafenac, A unique Nonsteroidal prodrug with
potential utility in the treatment of trauma induced ocular inflammation: II. In vivo
bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(4):371-
7- Aaronson A, Achiron A, Tuuminen R. Clinical Course of Pseudophakic Cystoid Macular Edema Treated with Nepafenac. J Clin Med. 2020, 9(9), 3034; https://doi.org/10.3390/jcm9093034
8-Popovic MM, Muni RH, Nichani P, Kertes PJ. Topical Nonsteroidal Anti-inflammatory Drugs for
Pain Resulting from Intravitreal Injections: A Meta-Analysis. Ophthalmol Ret. 2020;4(5):461-
9-Mathys KC, Cohen KS. Impact of nepafenac 0.1% on macular thickness and post
operative visual acuity after cataract surgery in patients at low risk for cystoid macular
edema. Eye. 2010;24:90-96.
10- Tzelikis PF, Morato CS, Neves NT, Hida WT, Alves MR. Intraindividual comparison of
nepafenac 0.3% for the prevention of macular edema after phacoemulsification. J Cat &
Ref Surg. 2018;44(4):440-446.
11-Singh R, Alprem L, Jaffe GJ, Lehmann RP, Lim j et al. Evaluation of nepafenac in prevention of
macular edema following cataract surgery in patients with diabetic retinopathy. Clin
Ophthalmol. 2012; 6: 1259–1269. doi: 10.2147/OPTH.S31902.
12- Stock RA, Galvan DK, Godoy R, Bonamigo EL. Comparison of macular thickness by optical
coherence tomography measurements after uneventful phacoemulsification using ketorolac
trimethamine, nepafenac, vs a control group, preoperatively and postoperatively. Clin
13- Ellakwa AF, Badaway NM, Al Said MA. Evaluation of nepafenac eye drops in prevention of
macular edema following cataract surgery. Menoufia Med J. 2020;33(2):604-610.
14- Singh RP, Lehmann R, Martel J, Jong K, Pollack A, Tsorbatzoglou A et al. Nepafenac 0.3%
after cataract surgery in patients with diabetic retinopathy: Results of 2 randomized phase
3 studies. Ophthalmology. 2017;124(6):776-785.
15- Pollack A, Staurenghi G, Sager D, Mukesh B, Singh RP. Prospective randomized clinical trial
to evaluate the safety and efficacy of 0.1% treatment for the prevention of macular edema
associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol.
16- El Gharbway SA, Darwish EA, Abu Eleinen KG, Osman MH. Efficacy of addition of nepafenac
0.1% to steroid eye drops in prevention of post phaco macular edema in high risk eyes. Eur J
Ophthalmol. 2019;29(4): https://doi.org/10.1177/1120672118799626
17- Daani R, Viljanen A, Aaronson A, Tuuminen R. Pre-operative anti-inflammatory treatment of
diabetic patients does not improve recovery from cataract surgery when post operatively
treated with a combination of prednisolone acetate and nepafenac. Act Ophthalmol.
18- Campa C, Salsini, Perri P. Comparison of the efficacy of dexamethasone, nepafenac, and
bromofenac for preventing pseudophakic cystoid macular edema: an open-label,
prospective, randomized controlled trial. Curr Eye Res. 2018;43(3):362-367.
19- Sahin AK, Kukner AS, Ulas F, Dogan U. Effect of nepafenac 0.1% on retinal thickness after
cataract surgery in patient without risk factors for cystoid macular edema. Int J Ophthalmol.
20- Sarfraz MH, Haq RI, Mehboob MA. Effect of topical nepafenac inn prevention of macular
edema after cataract surgery in patients with non-proliferative diabetic retinopathy. Pak J
Med Sci. 2017; 33(1): 210–214. doi: 10.12669/pjms.331.11644.
Copyright (c) 2022 Arooj Amjad, Muhammad Shaheer, Hassan Tariq, Ammarah Rasheed
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
All research articles published in the Journal of Rawalpindi Medical College (JRMC) are fully open access: immediately freely available to read, download, and share. Copyrights of all articles published in JRMC are retained by the authors. First publication rights are granted to JRMC. The journal/publisher is not responsible for subsequent uses of the work.
All articles are published under the Creative Commons Attribution (CC BY-SA 4.0) license.